Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ESSA Pharma Inc EPIX

Healthcare Biotechnology
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a... see more

Recent & Breaking News (NDAQ:EPIX)

ESSA Pharma Announces First Patient Dosed in a Phase 1 Clinical Trial of EPI-7386 for Metastatic Castration-Resistant Prostrate Cancer

PR Newswire July 15, 2020

ESSA Pharma Presents Therapeutic Potential of EPI-7386 at the 2020 American Association for Cancer Research Virtual Annual Meeting II

Canada NewsWire June 22, 2020

ESSA Pharma to Present at Jefferies Virtual Healthcare Conference

PR Newswire May 27, 2020

ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 2020 Virtual American Urological Association (AUA) Annual Meeting

Canada NewsWire May 15, 2020

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2020

Canada NewsWire May 7, 2020

ESSA Pharma Announces FDA Allowance of the Clinical Investigation of EPI-7386 in Prostate Cancer

Canada NewsWire April 30, 2020

ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement

Canada NewsWire April 13, 2020

ESSA Pharma Submits IND for EPI-7386 for Prostate Cancer and Provides Business Update

Canada NewsWire March 31, 2020

Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies

Accesswire March 24, 2020

Realtor Credits New Immunotherapy for Destroying the Cancer That Threatened His Life

Livemoney March 2, 2020

ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders

Canada NewsWire February 27, 2020

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2019

Canada NewsWire February 13, 2020

ESSA Pharma Announces Multiple Abstracts Accepted for Presentation at Upcoming Medical and Scientific Symposia

Canada NewsWire February 10, 2020

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2019

Canada NewsWire December 19, 2019

Janpix, Inc. Announces Appointment of Sanford (Sandy) Zweifach as Executive Chairman to its Board of Directors

GlobeNewswire December 12, 2019

Encode Ideas, L.P. Announces the Initiation of Research Coverage on ESSA Pharma, Inc.

Newsfile November 11, 2019

ESSA Pharma Grants Stock Options

PR Newswire October 30, 2019

ESSA Pharma Presents Data on EPI-7386 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Canada NewsWire October 28, 2019

ESSA Announces Changes to its Board of Directors

Canada NewsWire October 18, 2019

ESSA Pharma Board of Directors Approves Stock Option Plan, RSU Plan and Option Grants

Canada NewsWire October 7, 2019